Metformin and Diabetic Kidney Disease: A Mini-Review on Recent Findings

Hamid Nasri¹, MD; Mahmoud Rafieian-Kopaei*², MD

¹Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan; ²Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

Received: Dec 04, 2013; Accepted: May 02, 2014; First Online Available: Sep 12, 2014

Abstract

Metformin, an oral anti-diabetic agent in the biguanide class is a widely prescribed drug to treat high blood glucose in patients with type 2 diabetes mellitus. Metformin has three different roles, including blood glucose regulatory effect, protection of kidney tubular cell by acting as an effective antioxidant and finally ameliorative effect on diabetic kidney disease through saving the podocytes. Therefore, diabetic patients may benefit from all of these three distinct ameliorative effects.

Key Words: Metformin; Kidney Disease; Diabetes; Anti-diabetic Agents

Introduction

Diabetes mellitus is now the major cause of end-stage renal failure around the world in both developed and underdeveloped countries[1,2]. It is the primary diagnosis causing renal failure in 20–40% of people starting treatment for end-stage kidney failure worldwide[2,4]. Vascular and glomerular damages have been found the main features of diabetic nephropathy, however tubular atrophy also plays a major role in the disease[3,4].

Mechanisms of Diabetic Kidney Disease

Apoptosis contributes to the development of diabetic kidney disease[5,6]. It is possible that high glucose enhances apoptosis, a form of programmed cell death displayed by cell shrinkage, DNA fragmentation or chromatin condensation in a variety of cell types, especially renal proximal tubular epithelial cells[7,8]. Moreover, diabetic kidneys are mainly prone to acute tubular injury in various clinical situations, such as dehydration or post renal obstruction[8-10]. It is also well determined that hyperglycemia by itself is an independent risk factor for acute tubular injury under these conditions. High blood glucose activates the generation of free radicals and oxidative stress in tubular cells. Reactive oxygen species (ROS) are thought to be important mediators for several biologic responses including proliferation and apoptosis[8-13]. Indeed, besides apoptosis of proximal tubular epithelial by hyperglycemia, other cell types including podocytes will also be affected by hyperglycemia[10-13]. Thus one of beneficial treatments in the diabetic kidney disease is using medication for inhibiting or reducing apoptosis to save renal tubular cells and podocytes. In a study on patients with type 2 diabetes mellitus (T2DM), inhibition of the rennin-angiotensin-aldosterone...
system using an angiotensin converting enzyme (ACE) inhibitor or blocking the effect of angiotensin II through using an angiotensin receptor blocker decreased the progression from normoalbuminuria to microalbuminuria\cite{12-19} and slowed the development of end-stage renal disease (ESRD)\cite{15-20}. Thus, the use of an ACE inhibitor or angiotensin receptor blocker (ARB) or combination of both is now standard therapy for patients with diabetic nephropathy along with glucose, lipid and blood pressure control\cite{2-9}.

**Renoprotective Effects of Metformin**

Metformin, an oral anti-diabetic agent in the biguanide class is a widely prescribed drug to treat high blood glucose in patients with T2DM\cite{21,22}. Recent studies have recognized that metformin possesses antioxidant effects, too. Reduction of apoptosis, in endothelial cells as well as inhibition of vascular endothelial cell dysfunction was also found during metformin treatment\cite{23-25}. The beneficial action of this drug is achieved through activation of adenosine monophosphate-activated protein kinase (AMPK). This enzyme plays an important role in protecting cellular functions under energy-restricted conditions. Many evidences, confirm that AMPK activation by metformin is secondary to its effect on the mitochondria as the primary target of this drug. There is evidence that the beneficial effect of metformin might be due to its mild inhibition of the mitochondrial respiratory chain, while the serious role of mitochondria in cell death is of significance, and protecting the mitochondria has become a pro-survival cell strategy \cite{16-25}. It is possible that the role of mitochondria in programmed cell death is associated with the release of apoptotic signaling molecules. ROS production by mitochondria may also lead significantly to cell injury. Some years ago, Morales et al found that gentamicin-induced renal tubular injury is abolished by metformin\cite{24}. It is clear that, reactive oxygen species play a key role in the toxicity of gentamicin, resulting in acute kidney injury, and gentamicin is a mitochondrial toxin that can imply its toxic effects when excreted by the kidney. Mitochondrial toxicity can also be mediated by ROS as mentioned above\cite{13,19,20,22-25}. ROS is normally produced at low levels by mitochondria, conversely under pathological situations the intracellular and intra mitochondrial ROS content may be increased. When in certain conditions, intracellular ROS content reaches a toxic level, results in oxidative damage to the mitochondria causing cell death and malfunctioning of the organ\cite{13,19,20,22-25}. To test the potential renoprotective effects of metformin against gentamicin-induced renal damage and also finding out whether postponed treatment with metformin in acute kidney injury exerts similar benefits on gentamicin renal toxicity, we conducted a study on rats. In this study, metformin protected and also improved gentamicin-induced acute renal injury, hence, this drug might be effective for protection of tubular cells\cite{27}. More recently, we also investigated the efficiency of co-administration of garlic juice and metformin for protection against gentamicin-kidney tubular injury in 70 rats. The results of this investigation showed that metformin and garlic extract or their combination have both curative and protective property against gentamicin renal-toxicity\cite{28}. Accordingly, Li and colleagues showed that co-administration of metformin and gentamicin for 13 days efficiently reversed gentamicin-induced kidney injury\cite{29}. Thus, these findings provide further evidence for the attribution of metformin in its kidney protective efficacy besides its well-known blood glucose regulatory action\cite{22-28}.

While, diabetic kidney disease is one of the most important complications of this illness\cite{29-36} and metformin is widely used in this patients, especially in T2DM, recently much attention has also been directed on the possible protective and ameliorative properties of metformin in diabetic renal disease. Hyperglycemia intensifies oxidative stress and generation of ROS, which have a critical role in the pathogenesis of diabetic renal disease\cite{23-30}. Indeed, metformin treatment caused significant restoration in diabetic renal disease-induced oxidative stress mRNA levels\cite{23-27}. Various evidences suggest that ROS overproduction may be the key starting event that results in long-term development of problems of diabetes. ROS generation by oxidative stress causes cell death\cite{20-27}. As it was mentioned previously, apoptosis is implicated in the
pathogenesis of diabetic nephropathy and ROS is an inducer of apoptosis in various cell types containing podocytes[22-27]. Interestingly Kim et al conducted a study using metformin in diabetic rats. They observed the repair of podocytes by metformin treatment in diabetic rats. They suggested that diabetes-induced podocyte loss in diabetic nephropathy could be diminished by metformin[37-40]. They also found that the density of podocytes decreases in diabetic rats along with increased albumin excretion. Podocyte apoptosis has been identified to associate with increasing albuminuria. Moreover, there are evidences for the role of intracellular ROS as potent inducers of podocyte apoptosis. Kim et al also observed that the phosphorylation of AMPK was decreased in the kidney of diabetic rats, and metformin could reestablish its alteration. Therefore, metformin might exert some of its effects by amendment of renal oxidative stress[34]. Thus one might suggest metformin to inhibit the advanced glycation end-products and improve the free-radical defense system, hence, preventing the diabetic renal injury[3].

It is well understood that the injury to the podocytes leads to occurrence of proteinuria[32-36]. Therefore the loss of glomerular podocytes precedes and predicts the onset of diabetic nephropathy and may be an early pathological manifestation of diabetic kidney disease. Metformin significantly decreased albuminuria in patients with T2D[34,39,40]. Previous studies have also shown the beneficial effects of metformin on reduction of macrovascular morbidity and mortality, suggesting anti-atherogenic, antioxidant and anti-inflammatory effects[21-25]. Furthermore, metformin significantly decreased albuminuria in patients with T2DM[40-43].

**Conclusion**

Therefore, it is reasonable to interpret that metformin has three different roles, including: blood glucose regulatory effect, protection of kidney tubular cell by acting as an effective antioxidant and finally ameliorative effect on diabetic kidney disease through saving the podocytes. Therefore, diabetic patients may benefit from all of these three distinct ameliorative effects. However, it should be noted that, according to the contraindication of metformin in the estimated glomerular filtration rates (eGFR) of less than 30 mL/minute, we cannot suggest this drug for renal tubular cell protection in human studies. Hence, we suggest to more investigation on this subject.

**Authors’ contribution**

H. Nasri and M. Rafieian-Kopaei wrote the manuscript equally.

**Conflict of Interest:** None

**References**

1. Nasri H. On the occasion of the world diabetes day 2013; diabetes education and prevention; a nephrology point of view. J Renal Inj Prev 2013;2(2):31-32.
2. Toluouian R, Hernandez T. Prediction of Diabetic Nephropathy: The need for a sweet biomarker. J Nephropharmacol 2013;2(1):4-5.
3. Nasri H. The awareness of chronic kidney disease and aging: the focus of world kidney day in 2014. J Nephroparmacol 2014;3(1):1-2.
4. Behradmanesh S, Derees F, Rafieian-Kopaei M. Effect of *Salvia officinalis* on diabetic patients. J Renal Inj Prev 2013;2(2):51-54.
5. Rafieian-Kopaei M. Medicinal plants and the human needs. J HerbMed Pharmacol 2012;1(1):1-2.
6. Rafieian-Kopaei: M. Medicinal plants for renal injury prevention. J Renal Inj Prev 2013;2(2):63-65.
7. Habib SL. Diabetes and renal tubular cell apoptosis. World J Diabetes 2013; 4(2):27-30.
8. Amiri M, Nasri H. Secondary hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyroid Dis 2014;2(1):1-3.
9. Pickering JW, Endre ZH. The definition and detection of acute kidney injury. J Ren Inj Prev 2014; 3(1):21-25.
10. Tavafi M. Protection of renal tubules against gentamicin induced nephrotoxicity. J Ren Inj Prev 2012;2(1):5-6.
11. Hajivandi A, Amiri M. World Kidney Day 2014: Kidney disease and elderly. J Parathy Dis 2014; 2(1):3-4.
12. Nasri H. Acute kidney injury and beyond. J Renal Inj Prev 2012;1(1):1-2.
13. Appel G. Detecting and controlling diabetic nephropathy: What do we know? Cleve Clin J Med 2013;80(4);209-17.
Metformin and Diabetic Kidney Disease: A Mini-Review on Recent Findings

14. Hernandez GT, Nasri H. World Kidney Day 2014: increasing awareness of chronic kidney disease and aging. J Renal Inj Prev 2014;3(1):3-4.

15. Zorov DB. Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria. Kidney Int 2010;77(10):841-3.

16. Gobe GC, Morais C, Vesey DA, et al. Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. J Nephropathol 2013;2(3):154-65.

17. Baradaran A, Mahmoud Rafieian-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. J Renal Inj Prev 2012;2(1):15-21.

18. Nasri H, Rafieian-Kopaei M. Metformin improves diabetic kidney disease. J Nephropharmacol 2012; 1(1):1-2.

19. Sanadgol H, Abdani S, Tabatabaiee P, Mohammadi M. Protective effect of high dose short term statin therapy with normal saline in prevention of contrast-induced nephropathy among iodixanol-receiving patients. J Renal Inj Prev 2012;1(1):43-45.

20. Rafieian-Kopaei M, Baradaran A, Rafieian M. Plants antioxidants: from laboratory to clinic. J Nephropharmacol 2013;2(2):152-3.

21. Tavafi M. Complexity of diabetic nephropathy pathogenesis and design of investigations. J Renal Inj Prev 2013;2(2):59-62.

22. Rafieian-Kopaei M, Nasri H. Ginger and diabetic nephropathy. J Renal Inj Prev 2012;2(1):9-10.

23. Tavafi M. Diabetic nephropathy and antioxidants. J Nephropharmacol 2013;2(1):20-7.

24. Spasovski D. Renal markers for assessment of renal tubular and glomerular dysfunction. J Nephropharmacol 2013;2(2):23-25.

25. Sung JF, Choi HC. Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta. Biochem Biophys Res Commun 2012;421(3):599-604.

26. Baradaran A. Primary hyperparathyroidism and kidney; recent findings. J Parathy Dis 2014;2(1):7-10.

27. Rafieian-Kopaei M, Nasri H. Vitamin D therapy in diabetic kidney disease. J Nephropharmacol 2014; 3(1):3-4.

28. Rafieian-Kopaei M. Metformin and renal injury protection. J Ben Inj Prev 2013;2(3):91-92.

29. Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 2010; 77(10):861-9.

30. Amini FG, Rafieian-Kopaei M, Nematbakhsh M, et al. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci 2012;17(7):621-5.

31. Baradaran A, Rafieian-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. J Renal Inj Prev 2012;2(1):15-21.

32. Nasri H. The awareness of chronic kidney disease and aging; the focus of world kidney day in 2014. J Nephropharmacol 2014;3(1):1-2.

33. Nasri H. Comment on: Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients. J Renal Inj Prev 2012;1(1):13-14.

34. Roshan B, Stanton RC. A story of microalbuminuria and diabetic nephropathy. J Nephropharmacol 2013; 2(4):234-40.

35. Rahimi Z, Mansouri Zavello O, et al. AT2R -1332 G; A polymorphism and diabetic nephropathy in type 2 diabetes mellitus patients. J Renal Inj Prev 2013; 2(3):97-101.

36. Kronbichler A, Mayer G. Nephrotic Syndrome: is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis? J Nephropharmacol 2014;3(1):1-3.

37. Kim J, Shon E, Kim CS, et al. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res 2012;2012:210821.

38. Khajehdehi P. Turmeric: Reemerging Asian traditional remedy. J Nephropharmacol 2014;234(1):31.

39. Nasri H. Impact of diabetes mellitus on parathyroid hormone in hemodialysis patients. J Parathy Dis 2013;1(1):9-11.

40. Nasri H. Renoprotective effects of garlic. J Renal Inj Prev 2012;2(1):27-28.

41. Nasri H, Behradmanesh S, Maghsoudi AR, et al. Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus; a randomized double blind clinical trial. J Renal Inj Prev 2014;3(1):31-34.

42. Nasri H, Rafieian-Kopaei M. Herbal medicine and diabetic kidney disease. J Nephropharmacol 2013; 2(1):1-2.

43. Hajivandi A, Amiri M. World Kidney Day 2014: Kidney disease and elderly. J Parathy Dis 2014; 2(1):5-6.